European Journal of Cancer
Volume 38, Issue 10 , Pages 1329-1334 , July 2002

Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer—results of the analysis of 670 patients with 11 years of follow-up

  • S.-D Costa

      Affiliations

    • Department of Obstetrics and Gynecology, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-69-6301-4527; fax: +49-69-6301-7034
    • ,
  • S Lange

      Affiliations

    • Department of Obstetrics and Gynecology, University of Marburg, Marburg, Germany
    • ,
  • K Klinga

      Affiliations

    • Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
    • ,
  • E Merkle

      Affiliations

    • Frauenklinik Berg des Olgahospitals, Stuttgart, Germany
    • ,
  • M Kaufmann

      Affiliations

    • Department of Obstetrics and Gynecology, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany

Received 16 April 2001 ,Revised 11 October 2001 ,Accepted 29 January 2002.

References 

  1. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor and patients characteristics in human breast cancer. J. Clin. Oncol. 1984;2:1102–1109
  2. Fernö M, Borg A, Johansson U, et al.  Southern Swedish Breast Cancer Study Group. Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples. Acta Oncol. 1990;29:129–135
  3. Pichon MF, Broet P, Magdelenat H, et al.  Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br. J. Cancer. 1996;73:1545–1551
  4. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone in human breast cancer. Correlation with nuclear processing of oestrogen receptor. J. Biol. Chem. 1978;253:2223–2228
  5. Geyer H, Braun A. Kernrezeptoren in östrogenrezeptor-negativen tumoren mit progesteronrezeptoren. Onkologie. 1987;10:79–82
  6. Kiang DT, Kollander R. Breast cancers negative for estrogen receptor but positive for progesterone receptor, a true entity. J. Clin. Oncol. 1987;5:662–666
  7. Albert SR, Ingle JN, Patrick RR, et al.  Comparison of estrogen receptor determinations by a biochemical ligand binding assay and immunhistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer. 1996;78:764–772
  8. Blanco G, Alavaikko M, Ojala A, et al.  Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients. Anticancer Res. 1984;4:383–390
  9. Hilsenbeck SG, Ravdin PM, de Morr CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in breast cancer. Breast Cancer Res. Treat. 1998;52:227–237
  10. Huseby RA, Ownby HE, Brooks S, Russo J. Breast Cancer Prognostic Study Associates. Evalutation of the predictive power of progesterone receptor levels in primary breast cancer: a comparison with other criteria in 559 cases with a mean follow-up of 74.8 Monate. Henry Ford Hospital Med. J. 1990;38:79–84
  11. Kinsel LB, Szabo E, Greene GL, Leight GS, McCarty KS. Immuncytochemical analysis of oestrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res. 1989;49:1052–1056
  12. McCarty Ks, Kinsel LB, Georgiade G, Leight G. Long-term prognostic implications of sex-steroid receptors in human breast cancer. Molec Endocrinol Steroidal Hormone Action 1990, 279–293.
  13. Nomura Y, Miura S, Koyama H, et al.  Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer. 1992;69:153–164
  14. Reed W, Hannisadal E, Boehler PJ, Gundersen S, Host H, Nesland JM. The prognostic value of p53 and c-erbB-2 Immunostaining is overrated for patients with lymph node negative breast carcinoma. Cancer. 2000;88:804–813
  15. Rudolph P, MacGrogan G, Bonichon F, et al.  Prognostic significance of Ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. Breast Cancer Res. Treat. 1999;55:61–71
  16. Stewart JF, Rubens RD, Millis RR, King RJB, Hayward JI. Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur. J. Cancer Clin. Oncol. 1983;19:1981–1987
  17. Williams MR, Todd JH, Ellis IO, et al.  Oestrogen receptors in primary and advanced breast cancer. An eight year review of 704 cases. Br. J. Cancer. 1987;55:67–73
  18. Winstanley J, Cooke T, George WD, et al.  The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br. J. Cancer. 1991;64:99–101
  19. Collett K, Hartveit F, Skjarven R, Mahle BO. Prognostic role of oestrogen and progesterone receptors in patients with breast cancer in relation to age and lymph node status. J. Clin. Pathol. 1996;49:920–925
  20. Kaufmann M, Klinga K, Kühn W, Abel U, Proliferations-Index . axillärer Lymphknotenstatus, Hormonrezeptoren und Alter als Prognosefaktoren beim primären Mammakarzinom. Geburtshilfe Frauenheilkunde. 1989;49:104–108
  21. Aamdal S, Børner S, Jørgensen O, Høst H, Eliassen G, Kallhus O. Estrogen receptors and long-term prognosis in breast cancer. Cancer. 1984;6:2525–2529
  22. Molino A, Turazza M, Bonetti F, et al.  Estrogen and progesterone receptors in breast cancer: correlation with clinical and pathological features and with prognosis. Oncology. 1992;49:82–88
  23. Wyss P, Rageth JC, Unger C, Hochuli E. Die prognostische und therapeutische Bedeutung der Steroidrezeptoren beim invasiven Mammakarzinom. Geburtshilfe Frauenheilkunde. 1992;52:611–616
  24. Klinga K, Kaufmann M, Runnebaum B, Kubli F. Distribution of oestrogen and progesterone receptors of primary tumor and lymph nodes in individual patients with breast cancer. Oncology. 1982;39:337–339
  25. Cox DR. Regression models and life tables. J.R. Stat. Soc. 1972;34:187–220
  26. Coradini D, Daidone MG, Boracchi P, et al.  Time-dependent relevance of steroid receptors in breast cancer. J. Clin. Oncol. 2000;18:2702–2709
  27. Lethaby AE, Mason BH, Harvey VJ, Holdaway IM. Survival of women with node negative breast cancer in the Auckland region. NZ Med J. 1996;109:330–333
  28. Clark GM. Prognostic and predictive factors. In:  Harris JR,  Lippman ME,  Morrow M,  Hellman S editor. Diseases of the Breast. Philadelphia: Lippincott-Raven; 1996;p. 461–485
  29. Silvestrini R, Daidone MG, Luisi A, et al.  Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J. Clin. Oncol. 1995;13:697–704
  30. Biesterfeld S, Schröder W, Steinhagen G, et al.  Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Anticancer Res. 1997;17:4723–4730
  31. Early Breast Cancer Trialists' Collaborative Group . Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467

PII: S0959-8049(02)00067-9

European Journal of Cancer
Volume 38, Issue 10 , Pages 1329-1334 , July 2002

Article Tools

* Image Usage & Resolution